Register for email alerts and news feeds:
This journal | BMJ Group
rss
Evidence-Based Medicine 2007;12:70; doi:10.1136/ebm.12.3.70
Copyright © 2007 by the BMJ Publishing Group Ltd.

Therapeutics

Continuing alendronate for an additional 5 years maintained bone mineral density in postmenopausal women

Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296:2927–38.[Abstract/Free Full Text]

Q In postmenopausal women with low bone mineral density (BMD) who had been receiving daily alendronate for a mean of 5 years, what is the effect of continuing alendronate treatment for 5 years compared with discontinuing it?

Clinical impact ratings GP/FP/Primary care ******{star} Endocrine ******{star} Rheumatology ******{star} Internal medicine *****{star}{star} Surgery—orthopaedics *****{star}{star}

Key Words: alendronate • bone density • bone density conservation agents • fractures • bone

The first 150 words of the full text of this article appear below.

METHODS

Formula Design: randomised placebo controlled trial (Fracture Intervention Trial [FIT] Long-term Extension [FLEX]).

Formula Allocation: unclear allocation concealment.*

Formula Blinding: blinded (clinicians, participants, data collectors, and outcome assessors).*

Formula Follow up period: 5 years.

Formula Setting: 10 clinical centres in the US.

Formula Patients: 1099 postmenopausal women (mean age 73 y, 97% white) who had had low femoral neck BMD (<0.68 g/cm2) and had been allocated to alendronate (5 mg/d for 2 y and 10 mg/d thereafter) in FIT. Exclusion criteria were total hip BMD <0.515 g/cm2 (T score <–3.5) or total hip BMD lower than that at FIT baseline.

Formula Intervention: alendronate, 5 mg/day (n = 329); alendronate, 10 mg/day (n = 333); or placebo (n = 437). All participants received calcium, 500 mg/day, and vitamin D, 250 U/day.

Formula Outcomes: total hip BMD. Secondary outcomes included BMD at femoral neck, trochanter, lumbar spine, and forearm and of the total body; fracture incidence; and adverse events.

Formula . . . [Full text of this article]

Cory Baillie, MD

Manitoba Clinic,
Winnipeg, Manitoba, Canada


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.